PT3024833T - Novos derivados de indolizina, o seu processo de preparação e as composições farmacêuticas que os contêm - Google Patents

Novos derivados de indolizina, o seu processo de preparação e as composições farmacêuticas que os contêm

Info

Publication number
PT3024833T
PT3024833T PT147586051T PT14758605T PT3024833T PT 3024833 T PT3024833 T PT 3024833T PT 147586051 T PT147586051 T PT 147586051T PT 14758605 T PT14758605 T PT 14758605T PT 3024833 T PT3024833 T PT 3024833T
Authority
PT
Portugal
Prior art keywords
production
pharmaceutical compositions
compositions containing
containing same
indolizine derivatives
Prior art date
Application number
PT147586051T
Other languages
English (en)
Portuguese (pt)
Inventor
Starck Jérôme-Benoît
Edward Paul Davidson James
Le Diguarher Thierry
Henlin Jean-Michel
Geneste Olivier
Le Tiran Arnaud
De Nanteuil Guillaume
Brooke Murray James
Chen I-Jen
Original Assignee
Vernalis R&D Ltd
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50023640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3024833(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vernalis R&D Ltd, Servier Lab filed Critical Vernalis R&D Ltd
Publication of PT3024833T publication Critical patent/PT3024833T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT147586051T 2013-07-23 2014-07-22 Novos derivados de indolizina, o seu processo de preparação e as composições farmacêuticas que os contêm PT3024833T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357265A FR3008976A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"

Publications (1)

Publication Number Publication Date
PT3024833T true PT3024833T (pt) 2017-10-06

Family

ID=50023640

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147586051T PT3024833T (pt) 2013-07-23 2014-07-22 Novos derivados de indolizina, o seu processo de preparação e as composições farmacêuticas que os contêm

Country Status (49)

Country Link
US (3) US9944620B2 (enExample)
EP (1) EP3024833B1 (enExample)
JP (1) JP6458029B2 (enExample)
KR (1) KR102007516B1 (enExample)
CN (1) CN105579450B (enExample)
AP (1) AP2016008990A0 (enExample)
AR (1) AR099913A1 (enExample)
AU (1) AU2014294867B2 (enExample)
BR (1) BR112016001328B1 (enExample)
CA (1) CA2918217C (enExample)
CL (1) CL2016000063A1 (enExample)
CR (1) CR20160031A (enExample)
CU (1) CU24380B1 (enExample)
CY (1) CY1119652T1 (enExample)
DK (1) DK3024833T3 (enExample)
DO (1) DOP2016000014A (enExample)
EA (1) EA030323B1 (enExample)
ES (1) ES2650814T3 (enExample)
FR (1) FR3008976A1 (enExample)
GT (1) GT201600017A (enExample)
HK (1) HK1222394A1 (enExample)
HR (1) HRP20171752T1 (enExample)
HU (1) HUE037498T4 (enExample)
IL (1) IL243742B (enExample)
JO (1) JO3310B1 (enExample)
LT (1) LT3024833T (enExample)
MA (1) MA38803A1 (enExample)
MD (1) MD4643C1 (enExample)
ME (1) ME02922B (enExample)
MX (1) MX365916B (enExample)
MY (1) MY178251A (enExample)
NI (1) NI201600015A (enExample)
NO (1) NO3024833T3 (enExample)
NZ (1) NZ716156A (enExample)
PE (1) PE20160240A1 (enExample)
PH (1) PH12016500057A1 (enExample)
PL (1) PL3024833T3 (enExample)
PT (1) PT3024833T (enExample)
RS (1) RS56451B1 (enExample)
RU (1) RU2693629C2 (enExample)
SA (1) SA516370448B1 (enExample)
SG (2) SG10201800580XA (enExample)
SI (1) SI3024833T1 (enExample)
TN (1) TN2016000014A1 (enExample)
TW (1) TWI511969B (enExample)
UA (1) UA119243C2 (enExample)
UY (1) UY35626A (enExample)
WO (1) WO2015011397A1 (enExample)
ZA (1) ZA201600350B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
HUE067314T2 (hu) 2017-09-22 2024-10-28 Jubilant Epipad LLC Heterociklusos vegyületek mint PAD gátlók
KR102782563B1 (ko) 2017-10-18 2025-03-14 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 이미다조-피리딘 화합물
FR3072679B1 (fr) * 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
ES3025805T3 (en) * 2019-05-13 2025-06-09 Ecolab Usa Inc 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
AU2022233461A1 (en) * 2021-03-12 2023-09-07 Eil Therapeutics, Inc. Compounds having tetrahydroindolizine-1-carboxamide as bcl-2 inhibitors
KR20240130749A (ko) * 2021-12-29 2024-08-29 에일 테라퓨틱스 인코포레이티드 Bcl-2 저해제
EP4525927A1 (en) 2022-05-20 2025-03-26 Novartis AG Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420879T1 (de) * 2001-09-19 2009-01-15 Aventis Pharma Sa Indolizine als kinaseproteinhemmer
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス, インク. プロテインキナーゼモジュレーターおよびその使用方法
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
ZA200702257B (en) * 2004-08-20 2009-06-24 Univ Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
AU2005277223C1 (en) * 2004-08-20 2009-05-21 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
CA2631777A1 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
US7902218B2 (en) 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
CA2682356C (en) 2007-04-16 2016-06-14 Abbott Laboratories 7-substituted indole mcl-1 inhibitors
US8263607B2 (en) 2007-05-22 2012-09-11 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
CN102007101A (zh) 2007-11-30 2011-04-06 生物区科学管理控股有限公司 作为抗菌剂的四氢-异喹啉ppat抑制剂
NZ587039A (en) 2008-02-13 2013-01-25 Gilead Connecticut Inc 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
AU2009215118B2 (en) 2008-02-15 2015-01-22 Tufts University A humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
EP2714681B1 (en) * 2011-05-25 2015-06-24 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
MX2014007729A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
EA201491259A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
US9126979B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EA201491265A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
MX2014007731A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
EP2609926B1 (en) 2011-12-30 2013-10-23 Jakob Hraschan Prevention or treatment of painful polyneuropathies by administration of an aluminosilicate
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008979B1 (fr) 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
HRP20171752T1 (hr) 2017-12-29
CA2918217A1 (fr) 2015-01-29
CN105579450B (zh) 2017-12-12
LT3024833T (lt) 2017-10-25
ME02922B (me) 2018-04-20
AP2016008990A0 (en) 2016-01-31
ZA201600350B (en) 2017-05-31
KR20160034387A (ko) 2016-03-29
ES2650814T3 (es) 2018-01-22
EP3024833A1 (fr) 2016-06-01
JP6458029B2 (ja) 2019-01-23
CU20160011A7 (es) 2016-05-30
EA030323B1 (ru) 2018-07-31
RU2016105999A3 (enExample) 2018-04-28
SG10201800580XA (en) 2018-03-28
KR102007516B1 (ko) 2019-08-05
CN105579450A (zh) 2016-05-11
IL243742A0 (en) 2016-04-21
SA516370448B1 (ar) 2018-12-12
HK1223360A1 (zh) 2017-07-28
IL243742B (en) 2019-06-30
BR112016001328B1 (pt) 2022-03-03
PE20160240A1 (es) 2016-04-30
SI3024833T1 (sl) 2017-12-29
US9944620B2 (en) 2018-04-17
RU2016105999A (ru) 2017-08-28
CA2918217C (fr) 2018-06-12
EP3024833B1 (fr) 2017-09-06
FR3008976A1 (fr) 2015-01-30
JP2016525536A (ja) 2016-08-25
CY1119652T1 (el) 2018-04-04
CR20160031A (es) 2016-04-04
RU2693629C2 (ru) 2019-07-03
MX2016000906A (es) 2016-05-05
HK1222394A1 (zh) 2017-06-30
CU24380B1 (es) 2019-02-04
MD20160016A2 (ro) 2016-07-31
NI201600015A (es) 2016-02-11
PL3024833T3 (pl) 2018-02-28
MD4643B1 (ro) 2019-08-31
MY178251A (en) 2020-10-07
NO3024833T3 (enExample) 2018-02-03
UA119243C2 (uk) 2019-05-27
RS56451B1 (sr) 2018-01-31
GT201600017A (es) 2018-10-08
DOP2016000014A (es) 2016-03-15
AU2014294867A1 (en) 2016-02-11
MA38803A1 (fr) 2017-10-31
WO2015011397A1 (fr) 2015-01-29
MD4643C1 (ro) 2020-03-31
HUE037498T2 (hu) 2018-08-28
UY35626A (es) 2015-02-27
BR112016001328A2 (enExample) 2017-07-25
AR099913A1 (es) 2016-08-31
HUE037498T4 (hu) 2018-11-28
TW201504238A (zh) 2015-02-01
CL2016000063A1 (es) 2016-08-19
AU2014294867B2 (en) 2018-10-04
EA201600124A1 (ru) 2016-07-29
US10414754B2 (en) 2019-09-17
TWI511969B (zh) 2015-12-11
US20160176848A1 (en) 2016-06-23
DK3024833T3 (en) 2017-12-18
PH12016500057B1 (en) 2016-03-28
TN2016000014A1 (fr) 2017-07-05
PH12016500057A1 (en) 2016-03-28
MX365916B (es) 2019-06-20
SG11201600318RA (en) 2016-02-26
NZ716156A (en) 2019-05-31
US20190359595A1 (en) 2019-11-28
JO3310B1 (ar) 2018-09-16
US20180186771A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
ZA201600350B (en) Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
AP4028A (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
IL266300B (en) Antecedents of glutarimide, their use, a pharmaceutical preparation based on them and methods for producing antecedents of glutarimide
ZA201600415B (en) Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same
IL241038A0 (en) A new salt of abacinostat, a related crystalline form, a method for their preparation and pharmaceutical preparations containing them
IL239146A0 (en) Aminocyclobutane derivatives, methods for their preparation and their use as drugs
IL246406A0 (en) History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
IL239873A0 (en) The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them
ZA201504691B (en) Novel veterinary pharmaceutical compositions and method for the production thereof
HUP1300393A2 (en) Quinazoline derivatives, process for the preparation thereof and pharmaceutical compositions comprising the same